These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 22407289)

  • 1. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.
    Chirmule N; Jawa V; Meibohm B
    AAPS J; 2012 Jun; 14(2):296-302. PubMed ID: 22407289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology Perspective.
    Wang YM; Wang J; Hon YY; Zhou L; Fang L; Ahn HY
    AAPS J; 2016 Mar; 18(2):395-403. PubMed ID: 26721560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.
    Smith A; Manoli H; Jaw S; Frutoz K; Epstein AL; Khawli LA; Theil FP
    J Immunol Res; 2016; 2016():2342187. PubMed ID: 27579329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.
    Chen X; Hickling T; Kraynov E; Kuang B; Parng C; Vicini P
    AAPS J; 2013 Oct; 15(4):1141-54. PubMed ID: 23990500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins.
    Kathman S; Thway TM; Zhou L; Lee S; Yu S; Ma M; Chirmule N; Jawa V
    AAPS J; 2016 Mar; 18(2):424-31. PubMed ID: 26786568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context.
    Bloem K; Hernández-Breijo B; Martínez-Feito A; Rispens T
    Ther Drug Monit; 2017 Aug; 39(4):327-332. PubMed ID: 28463887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.
    Shankar G; Arkin S; Cocea L; Devanarayan V; Kirshner S; Kromminga A; Quarmby V; Richards S; Schneider CK; Subramanyam M; Swanson S; Verthelyi D; Yim S;
    AAPS J; 2014 Jul; 16(4):658-73. PubMed ID: 24764037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development.
    Harth S; Frisch C
    Methods Mol Biol; 2021; 2261():291-306. PubMed ID: 33420997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.
    van Brummelen EM; Ros W; Wolbink G; Beijnen JH; Schellens JH
    Oncologist; 2016 Oct; 21(10):1260-1268. PubMed ID: 27440064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming immunogenicity associated with the use of biopharmaceuticals.
    Tovey MG; Legrand J; Lallemand C
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):623-31. PubMed ID: 22114889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of immunogenic response to protein therapeutics.
    Singh SK; Cousens LP; Alvarez D; Mahajan PB
    Biologicals; 2012 Sep; 40(5):364-8. PubMed ID: 22770604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of the T Cell Response to Protein Biopharmaceuticals.
    Meunier S; de Bourayne M; Hamze M; Azam A; Correia E; Menier C; Maillère B
    Front Immunol; 2020; 11():1550. PubMed ID: 32793213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact.
    Tatarewicz SM; Mytych DT; Manning MS; Swanson SJ; Moxness MS; Chirmule N
    Bioanalysis; 2014 Jun; 6(11):1509-23. PubMed ID: 25046051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Immunogenicity of Biologic Therapies.
    Garcês S; Demengeot J
    Curr Probl Dermatol; 2018; 53():37-48. PubMed ID: 29131036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody.
    Kernstock R; Sperinde G; Finco D; Davis R; Montgomery D
    AAPS J; 2020 Mar; 22(3):60. PubMed ID: 32185565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal Antibodies.
    Passey C; Suryawanshi S; Sanghavi K; Gupta M
    AAPS J; 2018 Feb; 20(2):35. PubMed ID: 29484520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.
    Gunn GR; Sealey DC; Jamali F; Meibohm B; Ghosh S; Shankar G
    Clin Exp Immunol; 2016 May; 184(2):137-46. PubMed ID: 26597698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations.
    Jahn EM; Schneider CK
    N Biotechnol; 2009 Jun; 25(5):280-6. PubMed ID: 19491045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs).
    Bano N; Ehlinger C; Yang TY; Swanson M; Allen S
    AAPS J; 2022 Aug; 24(5):93. PubMed ID: 36028587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.